Difference between revisions of "Periplakin"
m |
m |
||
| Line 1: | Line 1: | ||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
| − | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
|- | |- | ||
| Substrate peptide name | | Substrate peptide name | ||
| Line 44: | Line 44: | ||
| It forms multimers upon TG2 action | | It forms multimers upon TG2 action | ||
|- | |- | ||
| − | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:Tissue transglutaminase|*]] | [[Category:Tissue transglutaminase|*]] | ||
Latest revision as of 11:51, 10 March 2015
| Periplakin | |
|---|---|
| Substrate peptide name | Periplakin |
| Synonyms | 190 kDa paraneoplastic pemphigus antigen |
| Determination type | In vitro |
| Source | Homo sapiens |
| Subcellular localization | Cornified envelope |
| Swissprot ID | O60437 |
| Reactive glutamines | Not determined yet |
| Reactive lysines | Not determined yet |
| Substrate sequence | |
| Structure | No available crystal structure |
| Surface accessibility | |
| Disorder prediction | IUPred |
| Reference | PMID:12923681 |
| Notes | It forms multimers upon TG2 action |
